Progression-free survival and overall survival according to the presence or absence of MM-PCs in the bone marrow at day 100 after ASCT. (A,B) Progression-free survival (PFS) and overall survival (OS) for all patients included in the present analysis (N = 295). (C,D) PFS and OS among the subset of patients achieving CR (n = 147).